Adsilico Raises £10 Million for Virtual Medical Device Testing
Oct 27, 2026
Healthcare
NAVER D2SF Backs ImpriMed in $10 Million Bridge Round
Sep 19, 2026
NAVER D2SF invested in precision medicine company ImpriMed through a $10 million Series A2 bridge round led by LB Investment.
NAVER D2SF said in a press release that it invested in Silicon Valley based precision medicine company ImpriMed through a $10 million Series A2 bridge round. LB Investment led the round, with participation from Samsung Securities, Alois Ventures, BonAngels and Han River Partners.
ImpriMed combines analysis of live patient cancer cells with genomic, immunophenotypic and clinical data to support cancer treatment decisions and drug development. Its xCellSense platform keeps cancer cells viable outside the body for testing biological characteristics and drug sensitivity. The company says its AI models are trained on more than 3.5 million data points.
The company plans to seek FDA clearance and CLIA certification by the first quarter of 2027 for products covering blood cancers and blood infections. It is also pursuing approval in South Korea for software that predicts multiple myeloma prognosis and therapy response.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Nov 9 Groq seeks $8 billion valuation in Series B, up from $3.5 billion in August, Bloomberg reports Nov 9 European AI companies raised $27.6 billion in the first nine months of 2026, Tracxn says Nov 9 Marble Imaging raises €6 million led by Cherry Ventures for satellite imagery and AI analytics Nov 8 Hanwha moves to invest 70 billion won in robot-dog maker LionRobotics Nov 8 Thinking Machines Lab seeks $5 billion at a $40 billion valuation, with Accel to lead, report saysMore from Life Sciences
Nov 9 NYU Langone's Lang1 beats much larger AI models at predicting hospital outcomes Nov 9 NYU Langone AI tool PREVIA predicts PTSD risk from what trauma patients say in the emergency room Nov 8 Weill Cornell says patient data was entered into AI tools without authorisation for a radiology study Nov 8 Cleerly's AI plaque analysis beats usual chest-pain care in first randomised trial Nov 7 BRAINIAC hub receives £20 million for AI dementia clinicsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
INmune Bio and QCi Apply Quantum Computing to XPro Research
Oct 14, 2026
Life Sciences
Atlas Bio raises $12.5 million for virtual drug trials
Oct 27, 2026
Healthcare
BioStack Raises $9.5 Million for Medical AI Data Network
Oct 22, 2026
Funding
Pathos AI Raises $237 Million at $3 Billion Valuation
Oct 23, 2026
Funding
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
Oct 12, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.